证券代码：001217 证券简称：华尔泰 公告编号：2025-007 安徽华尔泰化工股份有限公司 2025 年 4 月 16 日，公司召开了第六届监事会第四次会议，以 3 票同意，0 票反对，0 票弃权的表决结果，审议通过了《关于 2024 年度日常关联交易确认 及 2025 年度日常关联交易预计的议案》。 本次关联交易事项无需提交股东大会审议。 关于 2024 年度日常关联交易确认及 2025 年度日常关联交易 预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 安徽华尔泰化工股份有限公司（以下简称"公司""本公司"）根据日常经 营情况与业务发展需要，按照《深圳证券交易所股票上市规则》等相关规定，对 2024 年度日常关联交易进行了审核与确认，并对 2025 年度日常关联交易进行了 合理预计。根据公司 2024 年度日常关联交易的实际情况，并结合公司业务发展 的需要，预计 2025 年度，公司与关联方嘉兴市中华化工有限责任公司（以下简 称"中华化工"）、池州新赛德颜料有限公司（以下简称"新赛德颜料"） ...

安徽华尔泰化工股份有限公司 2024 年度内部控制评价报告 安徽华尔泰化工股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求 （以下简称"企业内部控制规范体系"），结合安徽华尔泰化工股份有限公司（以 下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项监督的基 础上，公司董事会对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部 控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。 公司董事会、监事会及董事、监事、高级管理人员保证本报告不存在任何虚 假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担 个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能对实现上述目标提供合理保证。此外，由于情况的变 ...

安徽华尔泰化工股份有限公司 2024 年度会计师事务所履职情况评估报告 及审计委员会履行监督职责情况报告 （二）聘任会计师事务所履行的程序 公司于 2024 年 4 月 16 日召开的第五届董事会第十五次会议、第五届监事会 第十二次会议审议通过了《关于续聘会计师事务所的议案》，后该议案于 2024 年 5 月 9 日经 2023 年年度股东大会审议通过。公司董事会审计委员会对上述议 案发表了同意意见。 2024 年 12 月 31 日的财务报告内部控制的有效性进行了审计，同时对公司非经 营性资金占用及其他关联资金往来情况等进行核查并出具了专项报告。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》和《公司章程》等规定和要 求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会 审计委员会对会计师事务所 2024 年度履职评估及履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 容诚会计师事务所（特殊普通 ...

证券代码：001217 证券简称：华尔泰 公告编号：2025-010 安徽华尔泰化工股份有限公司 （津贴）方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、未在公司任职的董事、监事不发放津贴。 3、在公司任职的董事、监事、高级管理人员根据其在公司担任的具体管理 职务，按照公司相关薪酬与绩效考核管理制度发放薪酬，不另行发放津贴。 二、备查文件 1、《安徽华尔泰化工股份有限公司第六届董事会第四次会议决议》； 2、《安徽华尔泰化工股份有限公司第六届监事会第四次会议决议》； 3、《安徽华尔泰化工股份有限公司第六届董事会薪酬与考核委员会第一次 会议决议》。 关于 2025 年度董事、监事、高级管理人员薪酬 安徽华尔泰化工股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召 开了第六届董事会第四次会议和第六届监事会第四次会议，审议了《关于 2025 年度董事、监事、高级管理人员薪酬（津贴）方案的议案》，上述议案尚需提交 公司 2024 年年度股东大会审议，现将 2025 年董事、监事、高级管理人员薪酬（津 贴）方案公告如下： 一、薪酬（津贴） ...

证券代码：001217 证券简称：华尔泰 公告编号：2025-013 安徽华尔泰化工股份有限公司 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司第六届董事会 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件、交易所业务规则和《公司章程》等的规定。 4、会议召开的日期、时间： 现场会议召开时间：2025 年 5 月 9 日（星期五）14:00 网络投票时间： 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 经安徽华尔泰化工股份有限公司（以下简称"公司"）第六届董事会第四次 会议审议通过，公司将于 2025 年 5 月 9 日（星期五）召开 2024 年年度股东大会， 现将有关事项通知如下： 一、召开会议的基本情况 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 9 日 9:15-9:25，9:30-11:30 和 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 9 日 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 安徽华尔泰化工股份有限公司（以下简称"公司"）第六届监事会第四次会 议于 2025 年 4 月 16 日在公司会议室以现场会议的方式召开。会议通知已于 2025 年 4 月 3 日以电话、邮件方式送达。本次会议应出席监事 3 名，实际出席监事 3 名。会议由监事会主席吴澳洲先生主持。本次会议的出席人数、召集、召开程序 和议事内容均符合《中华人民共和国公司法》和《安徽华尔泰化工股份有限公司 章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 会议经审议做出了如下决议： （一）审议通过《关于<2024 年度监事会工作报告>的议案》 证券代码：001217 证券简称：华尔泰 公告编号：2025-004 安徽华尔泰化工股份有限公司 关于第六届监事会第四次会议决议公告 2024 年度，公司监事会严格按照《公司法》《公司章程》《监事会议事规 则》等相关法律法规及规范性文件的要求，切实维护公司和广大股东权益，认真 履行了监督职责。 具体内容详见公司同日刊登在巨潮资讯网（http:// ...

安徽华尔泰化工股份有限公司 关于第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：001217 证券简称：华尔泰 公告编号：2025-003 安徽华尔泰化工股份有限公司（以下简称"公司"）第六届董事会第四次会议 于 2025 年 4 月 16 日（星期三）在公司会议室以现场结合通讯的方式召开，董事 陈有仁先生、乔治武先生、娄耀辉先生、胡海川先生以通讯表决方式出席会议。 会议通知已于 2025 年 4 月 3 日以电话、邮件方式送达。本次会议应出席董事 9 名，实际出席董事 9 名。会议由董事长吴炜先生主持，公司全体监事、高级管理 人员列席了会议。本次会议的出席人数、召集、召开程序和议事内容均符合《中 华人民共和国公司法》和《安徽华尔泰化工股份有限公司章程》（以下简称"《公 司章程》"）的有关规定。 二、董事会会议审议情况 会议经审议做出了如下决议： （一） 审议通过《关于<2024 年度董事会工作报告>的议案》 董事会严格按照相关法律、行政法规和中国证监会的规定，编制了《2024 年度董事会工作报 ...

关于 2024 年度利润分配预案的公告 证券代码：001217 证券简称：华尔泰 公告编号：2025-012 安徽华尔泰化工股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、审议程序 安徽华尔泰化工股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召 开了第六届董事会第四会议和第六届监事会第四次会议，审议通过了《关于 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年年度股东大会审议。 二、利润分配预案基本情况 根据容诚会计师事务所（特殊普通合伙）出具的标准无保留意见的审计报告， 公司 2024 年度合并报表归属于母公司股东的净利润为 87,742,684.12 元，2024 年末可供分配的利润为 912,531,390.67 元。 公司 2024 年度母公司实现净利润 87,950,258.30 元，公司根据《公司法》和 《公司章程》等相关规定按 2024 年度母公司净利润的 10%提取法定盈余公积金 8,795,025.83 元，加上上年结转的未分配利润 868,512,572.91 元，减去 2023 年 ...

Revenue and Profitability - The company's revenue for Q1 2025 was CNY 470,703,009.57, representing a 19.25% increase compared to CNY 394,707,255.02 in the same period last year[5] - Net profit attributable to shareholders decreased by 48.90% to CNY 17,031,941.87 from CNY 33,329,636.28 year-on-year[5] - Basic and diluted earnings per share both dropped by 50.00% to CNY 0.05 from CNY 0.10[5] - Total operating revenue for the current period reached ¥470,703,009.57, an increase of 19.2% compared to ¥394,707,255.02 in the previous period[17] - Net profit for the current period was ¥17,031,941.87, a decrease of 48.9% from ¥33,329,636.28 in the previous period[18] - Earnings per share (EPS) for the current period was ¥0.05, down from ¥0.10 in the previous period[18] Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -119,955,149.82, a decline of 227.02% compared to CNY -36,681,164.13 in the previous year[5] - Operating cash flow for the current period was -119,955,149.82 CNY, a decline from -36,681,164.13 CNY in the previous period, indicating a worsening cash flow situation[19] - Total cash inflow from investment activities was 112,755,028.03 CNY, compared to 81,689,387.05 CNY in the previous period, showing a significant increase of approximately 38%[19] - Cash outflow from investment activities totaled 175,154,540.03 CNY, up from 123,985,474.21 CNY, resulting in a net cash flow from investment activities of -62,399,512.00 CNY, worsening from -42,296,087.16 CNY[19] - Cash inflow from financing activities was 168,000,000.00 CNY, an increase from 80,000,000.00 CNY in the previous period, reflecting a growth of 110%[20] - Net cash flow from financing activities improved to 137,299,833.33 CNY, compared to 79,429,782.33 CNY previously, indicating a positive trend[20] - Cash inflow from sales of goods and services was 398,114,029.45 CNY, down from 452,333,023.23 CNY, indicating a decrease of about 12%[19] - Total cash outflow from operating activities was 519,775,771.95 CNY, compared to 490,642,787.95 CNY in the previous period, reflecting an increase of approximately 6%[19] - The ending cash and cash equivalents balance decreased to 99,525,391.18 CNY from 224,797,981.10 CNY, representing a decline of approximately 56%[20] Assets and Liabilities - Total assets increased by 1.14% to CNY 3,612,128,866.66 from CNY 3,571,405,137.25 at the end of the previous year[5] - Total liabilities rose to ¥1,335,866,549.76, up from ¥1,313,024,647.37 in the prior period[16] - Total equity attributable to shareholders increased to ¥2,276,262,316.90, compared to ¥2,258,380,489.88 in the previous period[16] - Total current assets increased to CNY 1,000,712,193.72 from CNY 898,506,117.12, reflecting a growth of approximately 11.1%[14] - Cash and cash equivalents decreased to CNY 195,355,311.11 from CNY 229,756,286.42, a decline of about 14.9%[14] - The company’s fixed assets increased significantly to CNY 1,943,557,259.56 from CNY 847,256,014.48, indicating a growth of approximately 129%[14] Income and Expenses - Total operating costs amounted to ¥455,735,069.44, up 26% from ¥361,733,662.14 in the prior period[17] - Research and development expenses were ¥12,617,953.66, an increase of 16.6% from ¥10,820,632.11 in the previous period[17] - The company reported a financial expense of ¥141,247.49, a significant improvement from a financial income of -¥684,287.18 in the previous period[17] - Deferred income tax liabilities increased to ¥27,950,296.69 from ¥25,867,857.10 in the previous period[16] Other Key Developments - The company reported a significant increase in trading financial assets, which rose by 109.55% to CNY 130,285,600.00 due to increased structured deposits[10] - Accounts receivable increased by 301.05% to CNY 1,036,500.00, influenced by the credit rating of bank acceptance bills[10] - Investment income surged by 3,499.01% to CNY 4,794,500.00, primarily due to increased returns from financial products[10] - The company experienced a 40.68% increase in other income, totaling CNY 4,665,200.00, attributed to deferred income growth[10] - The company completed the energy-saving and environmental upgrade project for synthetic ammonia production, entering the trial production phase as planned[12] - The company plans to continue its investment in R&D, which has contributed to increased expenses and depreciation of fixed assets[7] - The company plans to continuously optimize production processes and equipment to achieve full production capacity[12] - The company has not yet audited the first quarter report, which may affect the reliability of the financial data presented[21]

Financial Performance - The company's operating revenue for 2024 was CNY 1,641,061,339.78, a decrease of 8.42% compared to CNY 1,791,934,857.07 in 2023[20]. - The net profit attributable to shareholders for 2024 was CNY 87,742,684.12, down 44.56% from CNY 158,276,025.09 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 78,779,358.67, a decline of 46.16% from CNY 146,311,474.97 in 2023[20]. - Basic earnings per share for 2024 were CNY 0.26, a decrease of 45.83% from CNY 0.48 in the previous year[20]. - The weighted average return on equity for 2024 was 3.95%, down from 7.42% in 2023[20]. - The company reported a significant decline in revenue from trading customers, which fell by 20.89% to ¥361,985,873.49, compared to ¥457,584,453.91 in 2023[57]. - The total revenue from the fine chemicals segment was CNY 397,130,572.82, with a year-on-year decrease of 5.81%[59]. - The total operating revenue for 2024 was ¥1,641,061,339.78, representing a decrease of 8.42% compared to ¥1,791,934,857.07 in 2023[56]. Cash Flow and Investments - The net cash flow from operating activities surged to CNY 433,848,636.45, an increase of 5,843.04% compared to CNY 7,300,112.05 in 2023[20]. - The total cash inflow from operating activities was approximately ¥1.97 billion, while cash outflow was about ¥1.54 billion, resulting in a net cash flow of approximately ¥433.85 million[74]. - The cash flow from investment activities saw a significant decline of 64.76%, primarily due to a reduction in the redemption of financial products[74]. - The net cash flow from financing activities decreased by 87.90%, attributed to pledged certificates of deposit[74]. - The company invested 4,959.79 million yuan in R&D, a decrease of 10.64% year-on-year[43]. Production and Capacity - The company has an annual production capacity of 400,000 tons of nitric acid, 600,000 tons of sulfuric acid, and 300,000 tons of hydrogen peroxide, leading the market in nitric acid capacity and market share[42]. - The company has a design capacity of 250,000 tons for concentrated nitric acid, with a utilization rate of 118%[33]. - The company has a total capacity of 600,000 tons for sulfuric acid, with a utilization rate of 88%[33]. - The company has a production capacity of 30,000 tons for hydrogen peroxide, with a utilization rate of 96%[33]. - The company has a total of 15,000 tons of in-construction capacity for concentrated nitric acid[33]. Research and Development - The company has applied for 71 patents, including 16 invention patents, enhancing its technological innovation capabilities[36]. - The R&D center has been operational, focusing on projects such as the quality distillation of sulfur trioxide and carbon removal from hydrogen peroxide products[52]. - The company invested 55.8281 million yuan in projects funded by raised funds, with a cumulative investment of 738.3561 million yuan[88]. - The company is focusing on technological innovation and talent cultivation to reduce costs and improve production technology levels[101]. Environmental and Safety Compliance - The company complies with national environmental protection laws and regulations, executing the strictest emission limits for pollutants such as particulate matter, sulfur dioxide, and nitrogen oxides[174]. - The company has obtained environmental impact assessment approvals for all current and new projects, including a 100,000-ton nitric acid project approved in January 2005 and a 150,000-ton nitric acid construction project approved in December 2011[174]. - The company is committed to resource utilization and has implemented a project for comprehensive utilization of "three wastes" with approval received in December 2018[174]. - The company has established a comprehensive safety and environmental responsibility system, enhancing management and assessment methods for environmental compliance[178]. Governance and Shareholder Engagement - The company has a clear cash dividend policy that allows for adequate expression of opinions and protection of minority shareholders' rights[164]. - The company is committed to maintaining transparency and effective communication with stakeholders during this transition period[132]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with legal requirements[114]. - The company has outlined its commitment to shareholder engagement through regular meetings and updates[126]. Market Expansion and Strategic Initiatives - The company is actively expanding its overseas market presence and enhancing its environmental safety measures in response to stricter regulations[30]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products were not detailed in the call[131]. - The company is responding to the explosive growth in demand for wet chemicals in the domestic chip industry by accelerating the development of electronic chemicals[98]. - The company plans to enhance its digital marketing strategy, expecting a 40% increase in online sales[142]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,237, with 846 in production, 45 in sales, 260 in technical roles, 13 in finance, and 73 in administration[159]. - The company emphasizes a performance-oriented compensation system, integrating basic salary guarantees with incentive pay to foster talent development[160]. - The training plan includes various programs aimed at enhancing employee skills and leadership capabilities, ensuring continuous professional growth[161]. - Research and development (R&D) personnel increased by 6.86% from 204 to 218, with the proportion of R&D personnel in the company rising from 16.00% to 17.62%[72].